

Title (en)
Immunostimulatory polynucleotide/immunomodulatory molecule conjugates

Title (de)
Immunostimulierende Oligonucleotidkonjugate

Title (fr)
Conjugués polynucléotides immunostimulateurs/molécule immunomodulatrice

Publication
EP 1537877 A2 20050608 (EN)

Application
EP 05001324 A 19971009

Priority
• EP 97912831 A 19971009
• US 2811896 P 19961011

Abstract (en)
Immunostimulatory polynucleotide-immunomodulatory molecule conjugate compositions are disclosed. These compositions include a polynucleotide that is linked to an immunomodulatory molecule, which molecule comprises an antigen and may further comprise immunomodulators such as cytokines and adjuvants. The polynucleotide portion of the conjugate includes at least one immunostimulatory oligonucleotide sequence (ISS). Methods of modulating an immune response upon administration of the polynucleotide-immunomodulatory conjugate preparation to a vertebrate host are also disclosed.

IPC 1-7
A61K 39/385; A61K 39/39; A61K 39/36; C12N 15/11

IPC 8 full level
A61K 39/385 (2006.01); **C12N 15/09** (2006.01); **A61K 31/7088** (2006.01); **A61K 39/00** (2006.01); **A61K 39/36** (2006.01); **A61K 39/39** (2006.01); **A61K 47/48** (2006.01); **A61P 37/02** (2006.01); **C12N 15/117** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP US)
A61K 39/36 (2013.01 - EP US); **A61K 39/385** (2013.01 - EP US); **A61K 47/54** (2017.07 - EP US); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **C12N 15/117** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US); **A61K 2039/55516** (2013.01 - EP US); **A61K 2039/55522** (2013.01 - EP US); **A61K 2039/55561** (2013.01 - EP US); **A61K 2039/57** (2013.01 - EP US); **A61K 2039/6025** (2013.01 - EP US); **C12N 2310/17** (2013.01 - EP US); **C12N 2310/313** (2013.01 - EP US); **C12N 2310/315** (2013.01 - EP US); **C12N 2310/3513** (2013.01 - EP US); **Y02A 50/30** (2017.12 - EP US)

Citation (applicant)
• WO 9602555 A1 19960201 - UNIV IOWA RES FOUND [US]
• KRIEG ET AL., NATURE, vol. 374, 1995, pages 546 - 549
• YAMAMOTO ET AL., MICROBIOL. IMMUNOL., vol. 36, 1992, pages 983
• BALLAS ET AL., J. IMMUNOL., vol. 157, 1996, pages 1840
• KLINMAN ET AL., J. IMMUNOL., vol. 158, 1997, pages 3635
• MALLEY, J. REPROD. IMMUNOL., vol. 16, 1989, pages 173 - 86
• JIANG ET AL., J. BIOL. STAND., vol. 14, 1986, pages 103 - 9
• BRADLEY ET AL., J. MED. VIROL., vol. 14, 1984, pages 373 - 86
• JAMES ET AL., N. ENGL. J. MED., vol. 332, 1995, pages 1262 - 6
• LEA ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1307, 1996, pages 263
• BLISS ET AL., J. IMMUNOL., vol. 156, 1996, pages 887 - 894
• AZUMA, I.: "Synthetic Immunoadjuvants: Application to Non-Specific Host Stimulation and Potentiation of Vaccine Immunogenicity", VACCINE, vol. 10, 1992, pages 1000, XP023710678, DOI: doi:10.1016/0264-410X(92)90108-V
• POCKLEY, A.G.; MONTGOMERY, P.C.: "In vivo Adjuvant Effect of Interleukins 5 and 6 on Rat Tear IgA Antibody Responses", IMMUNOLOGY, vol. 73, 1991, pages 19 - 23, XP002924708
• ADAM, A.; LEDERER, E.: "Muramyl peptides as Immunomodulators", ISI ATLAS OF SCIENCE, vol. 205, 1988
• CLEMENTS, J.D. ET AL.: "Adjuvant Activity of Escherichia coli Heat-labile Enterotoxin and Effect on the Induction of Oral Tolerance in Mice to Unrelated Protein Antigens", VACCINE, vol. 6, 1988, pages 269, XP023709734, DOI: doi:10.1016/0264-410X(88)90223-X
• BEN AHMEIDA, E.T.S. ET AL.: "Immunopotential of Local and Systemic Humoral Immune Responses by ISCOMs, Liposomes and FCA: Role in Protection Against Influenza A in Mice", VACCINE, vol. 11, 1993, pages 1302, XP023710484, DOI: doi:10.1016/0264-410X(93)90099-J
• GUPTA, R.K. ET AL.: "Adjuvants -- A Balance Between Toxicity and Adjuvanticity", VACCINE, vol. 11, 1993, pages 290 - 308
• CHANG ET AL.: "Nasal Drug Delivery", 1992, MARCEL DEKKER, article "Treatise on Controlled Drug Delivery"
• FRALEY ET AL., TRENDS BIOCHEM. SCI., vol. 6, no. 77, 1981
• MANNINO ET AL., BIOTECHNIQUES, vol. 6, 1988, pages 682

Citation (examination)
• WO 9911275 A2 19990311 - UNIV CALIFORNIA [US]
• RAZ E ET AL.: "PREFERENTIAL INDUCTION OF A TH1 IMMUNE RESPONSE AND INHIBITION OF SPECIFIC IGE ANTIBODY FORMATION BY PLASMID DNA IMMUNIZATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 93, 1 May 1996 (1996-05-01), pages 5141 - 5145, XP002058360, ISSN: 0027-8424, DOI: 10.1073/PNAS.93.10.5141

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Designated extension state (EPC)
LT SI

DOCDB simple family (publication)
WO 9816247 A1 19980423; AT E292980 T1 20050415; AU 4992197 A 19980511; CA 2268825 A1 19980423; CA 2268825 C 20060418; DE 69733020 D1 20050519; DE 69733020 T2 20060216; EP 0930893 A1 19990728; EP 0930893 B1 20050413; EP 1537877 A2 20050608; EP 1537877 A3 20050803; ES 2241042 T3 20051016; JP 2001503254 A 20010313; JP 4111403 B2 20080702; US 2003232780 A1 20031218; US 2004006010 A1 20040108; US 6610661 B1 20030826; US 7208478 B2 20070424

DOCDB simple family (application)

US 9719004 W 19971009; AT 97912831 T 19971009; AU 4992197 A 19971009; CA 2268825 A 19971009; DE 69733020 T 19971009;
EP 05001324 A 19971009; EP 97912831 A 19971009; ES 97912831 T 19971009; JP 51864998 A 19971009; US 30803600 A 20000216;
US 39409203 A 20030320; US 39438703 A 20030320